Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2020 Filed Aug 17, 2020 15:16 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 13,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023637 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,173 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:52 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 232.303 | $0.00 Strike: $118.38 | $0.00 |
DisclosureSEC source: 0000911916-20-000159 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,983.63 Underlying: Common Stock · 232.303 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:32 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,077.229 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000101 · edgar.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,674.007 Underlying: Common Stock · 1,077.229 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:32 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $120.68 | $0.00 |
DisclosureSEC source: 0000911916-20-000101 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,751.327 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 13.848 phantom stock units accrued on April 30, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:18 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 277.722 | $0.00 Strike: $99.02 | $0.00 |
DisclosureSEC source: 0000911916-20-000086 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,237.479 Underlying: Common Stock · 277.722 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 10.882 phantom stock units accrued on January 31, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,647 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 6,647 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,647 | $172.21 | $1,144,662.59 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $170.82 to $172.75. The price reported above reflects the weighted average sale price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,647 | $43.63 | $290,008.61 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,647 Underlying: ResMed Common Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $157.43 | $1,047,054.29 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.44 to $158.49. The price reported above reflects the weighted average sale price. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:42 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 184.564 | $0.00 Strike: $149.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000008 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,948.875 Underlying: Common Stock · 184.564 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.770 phantom stock units accrued on October 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,298 Underlying: ResMed Common Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $149.64 | $995,282.24 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.09 to 149.84. The price reported above reflects the weighted average sale price. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 01:36 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,370 | $149.26 | $204,488.94 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 0 Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 01:36 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 1,370 F1 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. F2 · ownership.nature: Mr. and Mrs. Farrell retain dispositive power over foundation holdings. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 01:36 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 8,970 F1 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 59,894 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,894 Underlying: ResMed Common Stock · 59,894 shares Expires 2026-11-21 F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2020, 2021 and 2022. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 65,802 | $146.34 | $9,629,464.68 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 23, 2019 02:15 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 117,971 | $146.34 | $17,263,876.14 |
DisclosureSEC source: 0001127602-19-033626 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,502 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · derivative · entry 9 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,949 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F8 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 4,495 | $143.88 | $646,740.60 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 7 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,531 F7 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,973 | $143.88 | $427,755.24 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 6 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,026 F6 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,417 | $143.88 | $491,637.96 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,999 F5 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8 | $145.17 | $1,161.36 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,416 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,070 | $144.47 | $443,532.11 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,424 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $144.13 to $145.02. The price reported above reflects the weighted average sale price. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,573 | $143.48 | $512,643.32 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,494 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $143.12 to 144.12. The price reported above reflects the weighted average sale price. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 183.40 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:18 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 8,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031078 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,232 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $129.83 | $863,492.68 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $129.57 to $130.16. The price reported above reflects the weighted average sale price. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 174.466 | $0.00 Strike: $136.13 | $0.00 |
DisclosureSEC source: 0000911916-19-000171 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,752.541 Underlying: Common Stock · 174.466 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 11.305 phantom stock units accrued on July 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,251 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $137.38 | $913,714.38 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $136.51 to 139.80. The price reported above reflects the weighted average sale price. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 18:11 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-028093 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 01:05 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 17,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F3 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on August 14, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,902 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · shares: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $132.35 | $880,259.85 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $131.35 to 132.86. The price reported above reflects the weighted average sale price. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 01:05 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-026648 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,553 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 6,651 | $123.76 | $823,127.76 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.23 to $124.06. The price reported above reflects the weighted average sale price. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 19:48 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-024247 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 20:17 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 204.161 | $0.00 Strike: $116.33 | $0.00 |
DisclosureSEC source: 0000911916-19-000145 · edgar.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,566.77 Underlying: Common Stock · 204.161 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,204 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 5,211 | $118.32 | $616,575.94 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,337 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.87 to 118.79. The price reported above reflects the weighted average sale price. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,440 | $117.56 | $169,286.40 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,548 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.84 to $117.82. The price reported above reflects the weighted average sale price. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 23:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-021406 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 13, 2019 Filed May 14, 2019 20:13 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-018474 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,855 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F5 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.